| abstract |
The present invention relates to conjugates of a protein drug and two or more P / A peptides and pharmaceutical compositions comprising them. The conjugates of the invention exhibit an advantageously lower immunogenicity compared to the same unmasked protein drugs as well as a favorable safety and tolerability profile, which makes them particularly suitable for therapeutic use. The conjugates further exhibit a longer plasma half-life and, therefore, a prolonged duration of action compared to the same unmasked protein drugs, which allows a reduction in the frequency of administration and, consequently, in the weight adverse effects. The invention also relates to methods for preparing such conjugates, as well as activated P / A peptides that are useful as synthetic intermediates in the preparation of the conjugates. |